DUSP5 suppresses esophageal squamous cell carcinoma by counteracting macrophage-derived AREG-ERK1/2 signaling and disrupting an oncogenic ERK1/2-ELK1-DUSP5 feedback circuitry

Codipilly DC, Wang KK. Squamous cell carcinoma of the esophagus. Gastroenterol Clin North Am. 2022;51:457–84.

Google Scholar 

Lam AK. Introduction: Esophageal squamous cell carcinoma-current status and future advances. Methods Mol Biol. 2020;2129:1–6.

Google Scholar 

Waters JK, Reznik SI. Update on management of squamous cell esophageal cancer. Curr Oncol Rep. 2022;24:375–85.

Google Scholar 

Wu H, Leng X, Liu Q, Mao T, Jiang T, Liu Y, et al. Intratumoral microbiota composition regulates chemoimmunotherapy response in esophageal squamous cell carcinoma. Cancer Res. 2023;83:3131–44.

Google Scholar 

Su J, Wu G, Ye Y, Zhang J, Zeng L, Huang X, et al. NSUN2-mediated RNA 5-methylcytosine promotes esophageal squamous cell carcinoma progression via LIN28B-dependent GRB2 mRNA stabilization. Oncogene. 2021;40:5814–28.

Google Scholar 

Zhao Y, Li Y, Zhu R, Feng R, Cui H, Yu X, et al. RPS15 interacted with IGF2BP1 to promote esophageal squamous cell carcinoma development via recognizing m(6)A modification. Signal Transduct Target Ther. 2023;8:224.

Google Scholar 

Chuang HC, Tan TH. MAP4K Family Kinases and DUSP Family Phosphatases in T-Cell Signaling and Systemic Lupus Erythematosus. Cells. 2019;8:1433.

Google Scholar 

Kutty RG, Talipov MR, Bongard RD, Lipinski RAJ, Sweeney NL, Sem DS, et al. Dual Specificity Phosphatase 5-substrate interaction: a mechanistic perspective. Compr Physiol. 2017;7:1449–61.

Google Scholar 

Liang M, Li Y, Zhang K, Zhu Y, Liang J, Liu M, et al. Host factor DUSP5 potently inhibits dengue virus infection by modulating cytoskeleton rearrangement. Antivir Res. 2023;215:105622.

Google Scholar 

Wu Z, Xu L, He Y, Xu K, Chen Z, Moqbel SAA, et al. DUSP5 suppresses interleukin-1β-induced chondrocyte inflammation and ameliorates osteoarthritis in rats. Aging. 2020;12:26029–46.

Google Scholar 

Wang R, Bao HB, Du WZ, Chen XF, Liu HL, Han DY, et al. P68 RNA helicase promotes invasion of glioma cells through negatively regulating DUSP5. Cancer Sci. 2019;110:107–17.

Google Scholar 

Liu T, Sun H, Liu S, Yang Z, Li L, Yao N, et al. The suppression of DUSP5 expression correlates with paclitaxel resistance and poor prognosis in basal-like breast cancer. Int J Med Sci. 2018;15:738–47.

Google Scholar 

Aurtenetxe O, Zaldumbide L, Erramuzpe A, López R, López JI, Cortés JM, et al. DUSP5 expression associates with poor prognosis in human neuroblastoma. Exp Mol Pathol. 2018;105:272–8.

Google Scholar 

Roskoski R Jr. ERK1/2 MAP kinases: structure, function, and regulation. Pharm Res. 2012;66:105–43.

Google Scholar 

Lucas RM, Luo L, Stow JL. ERK1/2 in immune signalling. Biochem Soc Trans. 2022;50:1341–52.

Google Scholar 

Martin-Vega A, Cobb MH. Navigating the ERK1/2 MAPK Cascade. Biomolecules. 2023;13:1555.

Google Scholar 

Lannigan DA. ERK1/2-RSK2 signaling in regulation of ERα-mediated responses. Endocrinology. 2022;163:bqac106.

Google Scholar 

Carmona-Rosas G, Alcántara-Hernández R, Hernández-Espinosa DA. Dissecting the signaling features of the multi-protein complex GPCR/β-arrestin/ERK1/2. Eur J Cell Biol. 2018;97:349–58.

Google Scholar 

Gurevich VV, Gurevich EV. GPCR-dependent and -independent arrestin signaling. Trends Pharm Sci. 2024;45:639–50.

Google Scholar 

Li Q, Li Z, Luo T, Shi H. Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy. Mol Biomed. 2022;3:47.

Google Scholar 

Li J, Guo Y, Duan L, Hu X, Zhang X, Hu J, et al. AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling. Oncotarget. 2017;8:33694–703.

Google Scholar 

Estrada CC, Maldonado A, Mallipattu SK. Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities. J Am Soc Nephrol. 2019;30:187–200.

Google Scholar 

Xu JC, Chen TY, Liao LT, Chen T, Li QL, Xu JX, et al. NETO2 promotes esophageal cancer progression by inducing proliferation and metastasis via PI3K/AKT and ERK pathway. Int J Biol Sci. 2021;17:259–70.

Google Scholar 

Liu B, Zhang B, Qi J, Zhou H, Tan L, Huang J, et al. Targeting MFGE8 secreted by cancer-associated fibroblasts blocks angiogenesis and metastasis in esophageal squamous cell carcinoma. Proc Natl Acad Sci USA 2023;120:e2307914120.

Google Scholar 

Chen L, Zhu S, Liu T, Zhao X, Xiang T, Hu X, et al. Aberrant epithelial cell interaction promotes esophageal squamous-cell carcinoma development and progression. Signal Transduct Target Ther. 2023;8:453.

Google Scholar 

Macleod K, Leprince D, Stehelin D. The ETS gene family. Trends Biochem Sci. 1992;17:251–6.

Google Scholar 

Buchwalter G, Gross C, Wasylyk B. ETS ternary complex transcription factors. Gene. 2004;324:1–14.

Google Scholar 

Kasza A. IL-1 and EGF regulate expression of genes important in inflammation and cancer. Cytokine. 2013;62:22–33.

Google Scholar 

Dhulipal PD. ETS oncogene family. Indian J Exp Biol. 1997;35:315–22.

Google Scholar 

Yan Q, Ni C, Lin Y, Sun X, Shen Z, Zhang M, et al. ELK1 enhances pancreatic cancer progression via LGMN and correlates with poor prognosis. Front Mol Biosci. 2021;8:764900.

Google Scholar 

Cui D, Li J, Zhu Z, Berk M, Hardaway A, McManus J, et al. Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation. J Clin Invest. 2023;133:e161913.

Google Scholar 

Yang B, Wang H, Xiao J, Chen W, Chen W. ELK1/KIFC1 axis promotes breast cancer cell proliferation by regulating glutathione metabolism. J Obstet Gynaecol Res. 2023;49:2175–84.

Google Scholar 

Li P, Shi Y, Gao D, Xu H, Zou Y, Wang Z, et al. ELK1-mediated YTHDF1 drives prostate cancer progression by facilitating the translation of Polo-like kinase 1 in an m6A dependent manner. Int J Biol Sci. 2022;18:6145–62.

Google Scholar 

Ma J, Zeng S, Zhang Y, Deng G, Qu Y, Guo C, et al. BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma. Cancer Lett. 2017;411:117–29.

Google Scholar 

Li K, Liu Y, Ding Y, Zhang Z, Feng J, Hu J, et al. BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer. J Clin Invest. 2022;132:e161308.

Google Scholar 

Xie W, Li S, Guo H, Zhang J, Tu M, Wang R, et al. Androgen receptor knockdown enhances prostate cancer chemosensitivity by down-regulating FEN1 through the ERK/ELK1 signalling pathway. Cancer Med. 2023;12:15317–36.

Google Scholar 

Yang R, Li X, Wu Y, Zhang G, Liu X, Li Y, et al. EGFR activates GDH1 transcription to promote glutamine metabolism through MEK/ERK/ELK1 pathway in glioblastoma. Oncogene. 2020;39:2975–86.

Google Scholar 

Zou R, Shi W, Chang X, Zhang M, Tan S, Li R, et al. The DNA-dependent protein kinase catalytic subunit exacerbates endotoxemia-induced myocardial microvascular injury by disrupting the MOTS-c/JNK pathway and inducing profilin-mediated lamellipodia degradation. Theranostics. 2024;14:1561–82.

Google Scholar 

Lovell MA, Lynn BC, Fister S, Bradley-Whitman M, Murphy MP, Beckett TL, et al. A novel small molecule modulator of amyloid pathology. J Alzheimers Dis. 2016;53:273–87.

Google Scholar 

Fan W, Xing Y, Yan S, Liu W, Ning J, Tian F, et al. DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma. Cancer Cell Int. 2024;24:208.

Google Scholar 

Yang Z, Huang D, Meng M, Wang W, Feng J, Fang L, et al. BAF53A drives colorectal cancer development by regulating DUSP5-mediated ERK phosphorylation. Cell Death Dis. 2022;13:1049.

Google Scholar 

Tögel L, Nightingale R, Wu R, Chüeh AC, Al-Obaidi S, Luk I, et al. DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis. Sci Rep. 2018;8:1767.

Google Scholar 

Xie Z, Lin H, Huang Y, Wang X, Lin H, Xu M, et al. BAP1-mediated MAFF deubiquitylation regulates tumor growth and is associated with adverse outcomes in colorectal cancer. Eur J Cancer. 2024;210:114278.

Google Scholar 

Yan G. Lei W. Role of ELK1 in regulating colorectal cancer progression: miR-31-5p/CDIP1 axis in CRC pathogenesis. PeerJ. 2023;11:e15602.

Google Scholar 

Wang J, Luo J, Wu X, Li Z. ELK1 suppresses SYTL1 expression by recruiting HDAC2 in bladder cancer progression. Hum Cell. 2022;35:1961–75.

Google Scholar 

Rudisch A, Dewhurst MR, Horga LG, Kramer N, Harrer N, Dong M, et al. High EMT Signature Score of Invasive Non-Small Cell Lung Cancer (NSCLC) Cells Correlates with NFκB Driven Colony-Stimulating Factor 2 (CSF2/GM-CSF) Secretion by Neighboring Stromal Fibroblasts. PLoS One. 2015;10:e0124283.

Google Scholar 

Wu DM, Deng SH, Zhou J, Han R, Liu T, Zhang T, et al. PLEK2 mediates metastasis and vascular invasion via the ubiquitin-dependent degradation of SHIP2 in non-small cell lung cancer. Int J Cancer. 2020;146:2563–75.

Google Scholar 

Sheng K, Lu J, Zhao H. ELK1-induced upregulation of lncRNA HOXA10-AS promotes lung adenocarcinoma progression by increasing Wnt/β-catenin signaling. Biochem Biophys Res Commun. 2018;501:612–8.

Google Scholar 

Panebianco C, Trivieri N, Villani A, Terracciano F, Latiano TP, et al. Improving Gemcitabine sensitivity in pancreatic cancer cells by restoring miRNA-217 levels. Biomolecules. 2021;11:639.

Google Scholar 

Laliotis A, Vrekoussis T, Kafousi M, Sanidas E, Askoxilakis J, Melissas J, et al. Immunohistochemical study of pElk-1 expression in human breast cancer: association with breast cancer biologic profile and clinicopathologic features. Breast. 2013;22:89–95.

Google Scholar 

Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:103–19.

Google Scholar 

Mi K, Zeng L, Chen Y, Ning J, Zhang S, Zhao P, et al. DHX38 enhances proliferation, metastasis, and EMT progression in NSCLC through the G3BP1-mediated MAPK pathway. Cell Signal. 2024;113:110962.

Google Scholar 

Wang JL, Mu XY, Ma R, Bai XH, Zhao ZJ, Wang YY. Silencing UBQLN2 Enhances the Radiosensitivity of Esophageal Squamous Cell Carcinoma (ESCC) via Activating p38 MAPK. J Oncol. 2023;2023:2339732.

Google Scholar 

Liu Y, Yang LY, Chen DX, Chang C, Yuan Q, Zhang Y, et al. Tenascin-C as a potential biomarker and therapeutic target for esophageal squamous cell carcinoma. Transl Oncol. 2024;42:101888.

Google Scholar 

Goodwin CM, Waters AM, Klomp JE, Javaid S, Bryant KL, Stalnecker CA, et al. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Cancer Res. 2023;83:141–57.

Google Scholar 

Ostrowski SM, Fisher DE. Biology of Melanoma. Hematol Oncol Clin North Am. 2021;35:29–56.

Google Scholar 

Yang L, Zheng L, Chng WJ, Ding JL. Comprehensive analysis of ERK1/2 substrates for potential combination immunotherapies. Trends Pharm Sci. 2019;40:897–910.

Google Scholar 

Li Y, Yang Q. Effect of PD98059 on chemotherapy in patients with colorectal cancer through ERK1/2 pathway. J buon. 2019;24:1837–44.

Google Scholar 

Shin SH, Park SY, Kang GH. Down-regulation of dual-specificity phosphatase 5 in gastric cancer by promoter CpG island hypermethylation and its potential role in carcinogenesis. Am J Pathol. 2013;182:1275–85.

Google Scholar